Antidepressants: Past, Present and Future

1. Front Matter

   Pages I-XII

   PDF

2. Basic Principles: Pharmacologic Science

   1. Front Matter

      Pages 1-1

      PDF

   2. Biochemical and Physiological Processes in Brain Function and Drug Actions

      • W. D. Horst

      Pages 3-33

   3. General Principles of Pharmacokinetics

      • S. H. Preskorn, M. L. Catterson

      Pages 35-86

   4. Therapeutic Drug Monitoring of Antidepressants

      • M. J. Burke, S. H. Preskorn

      Pages 87-114

3. Basic Principles: Clinical Science

   1. Front Matter

      Pages 115-115

      PDF

   2. Biological Markers of Depression

      • T. J. Connor, B. E. Leonard

      Pages 117-148

   3. Quality of Life and Rating Scales of Depression

      • P. Bech

      Pages 149-167

4. Current Pharmacotherapy of Major Depressive Disorder

   1. Front Matter

      Pages 169-169

      PDF

   2. Overview of Currently Available Antidepressants

      • S. H. Preskorn, R. Ross

      Pages 171-183

   3. Tricyclic Antidepressants

      • M. Lader

      Pages 185-208

   4. Monoamine Oxidase Inhibitors

      • S. H. Kennedy, A. Holt, G. B. Baker

      Pages 209-239

   5. Selective Serotonin Reuptake Inhibitors

      • S. H. Preskorn, R. Ross, C. Y. Stanga

      Pages 241-262

   6. Other Antidepressants

      • S. H. Preskorn, R. Ross

      Pages 263-324

   7. Current Role of Herbal Preparations

      • D. Wheatley

      Pages 325-351

5. Use of Antidepressants in Special Populations

   1. Front Matter

      Pages 353-353

      PDF

   2. Children and Adolescents

      • J. F. Bober, S. H. Preskorn

      Pages 355-378

   3. Women

      • K. A. Yonkers, O. Brawman-Mintzer

      Pages 379-392

   4. Older Adults

      • S. Glover, W. F. Boyer

      Pages 393-420

   5. Bipolar Mood Disorders

      • R. D. Alarcon

      Pages 421-446

This book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tri- clic antidepressants and monoamine oxidase inhibitors had antidepressant p- perties. That discovery had three consequences. First, it brought simple and effective treatment to patients suffering from major depressive illnesses. Second, these discoveries, together with the discovery of lithium and chlorpromazine, began the remedicalization of psychiatry by making it clear that the treatment of many of the major psychiatric illnesses can be approached in the same way as other medical conditions. However, the most far-reaching effect was to provide the first clue as to what mechanisms might underlie antidepressant efficacy, a development that has led to an explosion in the number of available an- depressants and to their widespread use. The goal of this book is to provide a thorough review of the current status of antidepressants—how we arrived at this point in their evolution and where we are going in both the near and the long term. The book employs both a scientific and historical approach to accomplish these goals. The book is intended for practitioners who use antidepressants on a daily basis in their practice as well as for the student and researcher. Each will find that the book provides a comprehensive and logical approach to this important group of medications. The importance of the book is a function of its topic.

• antidepressants
• brain
• depression
• depressive disorder
• drug
• drug development
• genomics
• kinetics
• personality
• pharmacokinetics
• pharmacotherapy
• population
• psychiatry
• research
• serotonin

• Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine and Psychiatric Research Insitute, 1010 N. Kansas, Wichita, USA

  Sheldon H. Preskorn

• Feighner Research Institute, San Diego, USA

  John P. Feighner

• Neillsville, USA

  Christina Y. Stanga

• Ross Editorial, Independence, USA

  Ruth Ross

Policies and ethics